DE60016393D1 - Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe - Google Patents
Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebeInfo
- Publication number
- DE60016393D1 DE60016393D1 DE60016393T DE60016393T DE60016393D1 DE 60016393 D1 DE60016393 D1 DE 60016393D1 DE 60016393 T DE60016393 T DE 60016393T DE 60016393 T DE60016393 T DE 60016393T DE 60016393 D1 DE60016393 D1 DE 60016393D1
- Authority
- DE
- Germany
- Prior art keywords
- glp
- blooded
- ischemic
- tissue
- improve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
- 230000000302 ischemic effect Effects 0.000 title 1
- 230000002503 metabolic effect Effects 0.000 title 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 208000037816 tissue injury Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US302596 | 1999-04-30 | ||
US09/302,596 US6284725B1 (en) | 1998-10-08 | 1999-04-30 | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
PCT/US2000/011251 WO2000066138A2 (en) | 1999-04-30 | 2000-04-27 | Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue |
EP00926404A EP1173197B2 (de) | 1999-04-30 | 2000-04-27 | Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe |
Publications (3)
Publication Number | Publication Date |
---|---|
DE60016393D1 true DE60016393D1 (de) | 2005-01-05 |
DE60016393T2 DE60016393T2 (de) | 2006-02-02 |
DE60016393T3 DE60016393T3 (de) | 2012-07-12 |
Family
ID=23168436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60016393T Expired - Lifetime DE60016393T3 (de) | 1999-04-30 | 2000-04-27 | Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe |
Country Status (16)
Country | Link |
---|---|
US (3) | US6284725B1 (de) |
EP (2) | EP1512410A1 (de) |
JP (1) | JP2002543142A (de) |
CN (1) | CN1349409A (de) |
AT (1) | ATE283701T1 (de) |
AU (2) | AU777019B2 (de) |
CA (1) | CA2372947C (de) |
DE (1) | DE60016393T3 (de) |
ES (1) | ES2233366T5 (de) |
HK (1) | HK1046640A1 (de) |
IL (2) | IL145830A0 (de) |
MX (1) | MXPA01010859A (de) |
NO (1) | NO325601B1 (de) |
NZ (1) | NZ514610A (de) |
PT (1) | PT1173197E (de) |
WO (1) | WO2000066138A2 (de) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138486B2 (en) * | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US6849708B1 (en) * | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
US7259136B2 (en) * | 1999-04-30 | 2007-08-21 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating peripheral vascular disease |
US6429197B1 (en) | 1998-10-08 | 2002-08-06 | Bionebraska, Inc. | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US6329336B1 (en) * | 1999-05-17 | 2001-12-11 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US20090175821A1 (en) * | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
US20060160740A1 (en) * | 1999-10-21 | 2006-07-20 | Suad Efendic | Use of GLP-1 or analogs in treatment of stroke |
US6485938B1 (en) * | 1999-11-16 | 2002-11-26 | Zymogenetics, Inc. | Nucleic acid molecules that encodes human Zven1 |
CN1462191B (zh) * | 2000-05-19 | 2013-07-24 | 埃米林药品公司 | Glp-1用于制备治疗急性冠脉综合征的药物的用途 |
CA2395165C (en) | 2000-10-20 | 2012-05-22 | Mario Ehlers | Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide |
EP1346722B1 (de) | 2000-12-01 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz |
EA006160B1 (ru) * | 2001-02-16 | 2005-10-27 | Конджачем, Инк. | Долгоживущий глюкагоноподобный пептид 2(glp-2, гпп-2) для лечения желудочно-кишечных заболеваний и расстройств |
JP2002293799A (ja) * | 2001-03-29 | 2002-10-09 | Itoham Foods Inc | 新規ペプチド及びそれを含有する消化管運動抑制剤 |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7138105B2 (en) * | 2002-02-27 | 2006-11-21 | Pharmain | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
US20050260259A1 (en) * | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
US7635463B2 (en) | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
DE60327771D1 (de) | 2002-07-04 | 2009-07-09 | Zealand Pharma As | Glp-1 und behandlungsmethode für diabetes |
EP1546200A2 (de) | 2002-10-02 | 2005-06-29 | Zealand Pharma A/S | Stabilisierte exendin-4-verbindungen |
US7291589B2 (en) * | 2002-10-07 | 2007-11-06 | Zymogenetics, Inc. | Uses of human Zven proteins and polynucleotides |
US7790681B2 (en) | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
US20040209803A1 (en) * | 2002-12-19 | 2004-10-21 | Alain Baron | Compositions for the treatment and prevention of nephropathy |
WO2004056313A2 (en) * | 2002-12-17 | 2004-07-08 | Amylin Pharmaceuticals, Inc. | Prevention and treatment of cardiac arrhythmias |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
CA2820537C (en) | 2003-04-23 | 2015-10-20 | Valeritas, Inc. | Hydraulically actuated pump for fluid administration |
US20060286129A1 (en) * | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
PL1745078T3 (pl) | 2004-04-23 | 2009-12-31 | Conjuchem Biotechnologies Inc | Sposób oczyszczania koniugatów albumin |
US9089636B2 (en) | 2004-07-02 | 2015-07-28 | Valeritas, Inc. | Methods and devices for delivering GLP-1 and uses thereof |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
DK1888103T3 (da) * | 2005-04-11 | 2012-04-23 | Amylin Pharmaceuticals Inc | Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering |
TWI364292B (en) | 2005-06-30 | 2012-05-21 | Ipsen Pharma Sas | Glp-1 pharmaceutical compositions |
WO2007033140A2 (en) * | 2005-09-13 | 2007-03-22 | Zymogenetics, Inc. | Prok2 antagonists and methods of use |
US8039432B2 (en) * | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
EP1971372B1 (de) * | 2005-12-19 | 2018-11-14 | PharmaIN Corporation | Trägerzusammensetzungen mit hydrophobem kern zur abgabe von therapeutischen mitteln, herstellungs- und anwendungsverfahren damit |
US20070264130A1 (en) * | 2006-01-27 | 2007-11-15 | Phluid, Inc. | Infusion Pumps and Methods for Use |
ES2566058T3 (es) | 2006-03-30 | 2016-04-08 | Valeritas, Inc. | Dispositivo de suministro de fluidos de múltiples cartuchos |
ES2351527T3 (es) | 2006-05-30 | 2011-02-07 | Intarcia Therapeutics, Inc | Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración. |
NZ574524A (en) | 2006-08-09 | 2011-07-29 | Intarcia Therapeutics Inc | Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring |
EP2157967B1 (de) | 2007-04-23 | 2013-01-16 | Intarcia Therapeutics, Inc | Suspensionsformulierungen insulinotroper peptide und ihre verwendung |
US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
US8563527B2 (en) * | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
US20090176892A1 (en) * | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
WO2009102467A2 (en) | 2008-02-13 | 2009-08-20 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US20090287180A1 (en) * | 2008-05-19 | 2009-11-19 | Diperna Paul M | Disposable pump reservoir and related methods |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
CA2737461A1 (en) | 2008-09-19 | 2010-03-25 | Tandem Diabetes Care, Inc. | Solute concentration measurement device and related methods |
WO2010043566A2 (de) | 2008-10-17 | 2010-04-22 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem insulin und einem glp-1-agonisten |
HUE031900T2 (en) | 2008-12-10 | 2017-08-28 | Glaxosmithkline Llc | Pharmaceutical compositions containing Albiglutide |
EP2216042A1 (de) | 2009-02-09 | 2010-08-11 | Ipsen Pharma S.A.S. | GLP1-analoge pharmazeutische Zusammensetzungen |
EP2459251B1 (de) | 2009-07-30 | 2014-03-12 | Tandem Diabetes Care, Inc. | Infusionspumpensystem mit einwegkartusche mit druckentlüftung und druckfeedback |
LT2462246T (lt) | 2009-09-28 | 2017-11-27 | Intarcia Therapeutics, Inc | Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas |
US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
ES2855146T3 (es) | 2009-11-13 | 2021-09-23 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
EP2504019A2 (de) | 2009-11-25 | 2012-10-03 | ArisGen SA | Zusammensetzung zur verabreichung über die schleimhaut mit einem komplex aus einem peptid und einer kronenverbindung und/oder einem gegenion |
WO2011123943A1 (en) | 2010-04-09 | 2011-10-13 | Mount Sinai Hospital | Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist |
MX343360B (es) | 2010-04-27 | 2016-11-03 | Zealand Pharma As | Conjugados peptidicos de agonistas del receptor de glp-1 y gastrina y su uso. |
WO2011140176A1 (en) | 2010-05-04 | 2011-11-10 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
RU2013103763A (ru) | 2010-07-02 | 2014-08-10 | Ангиохем Инк. | Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения |
PT2611458T (pt) | 2010-08-30 | 2016-12-16 | Sanofi Aventis Deutschland | Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
US9950038B2 (en) | 2011-08-05 | 2018-04-24 | The Trustees Of The Universiy Of Pennsylvania | Methods and compositions for inhibiting delayed graft function |
PT2750699E (pt) | 2011-08-29 | 2015-11-03 | Sanofi Aventis Deutschland | Acelerómetro pendular |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
CN104144704B (zh) | 2011-11-03 | 2018-03-23 | 西兰制药公司 | Glp‑1受体激动剂肽胃泌素缀合物 |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
JP6224586B2 (ja) | 2012-07-10 | 2017-11-01 | 武田薬品工業株式会社 | 注射用製剤 |
AR091866A1 (es) | 2012-07-23 | 2015-03-04 | Zealand Pharma As | Analogos del glucagon |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
WO2014063239A1 (en) * | 2012-10-26 | 2014-05-01 | University Health Network | Peptides and methods for preventing ischemic tissue injury |
ES2688367T3 (es) | 2012-12-21 | 2018-11-02 | Sanofi | Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón |
TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
UA122767C2 (uk) | 2013-10-17 | 2021-01-06 | Зіленд Фарма А/С | Ацильований аналог глюкагону |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
CA2929459C (en) | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080154B1 (de) | 2013-12-13 | 2018-02-07 | Sanofi | Duale glp-1/gip-rezeptoragonisten |
EP3080152A1 (de) | 2013-12-13 | 2016-10-19 | Sanofi | Nicht-acylierte exendin-4-peptidanaloga |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
CN112957455A (zh) | 2014-01-09 | 2021-06-15 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂 |
SG11201604706TA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin aspart |
WO2015104311A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
BR112017008659A2 (pt) | 2014-10-29 | 2018-01-30 | Zealand Pharma As | ?métodos e compostos de agonista de gip? |
CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
AU2016247499B2 (en) | 2015-04-16 | 2020-09-03 | Zealand Pharma A/S | Acylated glucagon analogue |
JP6993235B2 (ja) | 2015-06-03 | 2022-01-13 | インターシア セラピューティクス,インコーポレイティド | インプラントの設置及び撤去システム |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
EP3458084B1 (de) | 2016-05-16 | 2020-04-01 | Intarcia Therapeutics, Inc | Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
EP3296746A1 (de) * | 2016-09-20 | 2018-03-21 | Université de Bourgogne | In-vitro-verfahren zur diagnose eines frühstadiums von darmischämie |
CN117384274A (zh) | 2016-12-09 | 2024-01-12 | 西兰制药公司 | 酰化的glp-1/glp-2双重激动剂 |
KR20190104039A (ko) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법 |
DE102020103987A1 (de) * | 2020-02-14 | 2021-08-19 | Eberhard Karls Universität Tübingen, Medizinische Fakultät | Agens zur Behandlung und Prophylaxe einer postischämischen Gewebeschädigung |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US61838A (en) * | 1867-02-05 | Eichaed ketcham | ||
US4196196A (en) | 1978-06-19 | 1980-04-01 | Tiholiz Ivan C | Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states |
US4976959A (en) * | 1986-05-12 | 1990-12-11 | Burroughs Wellcome Co. | T-PA and SOD in limiting tissue damage |
US6204259B1 (en) | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5512549A (en) † | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US6107329A (en) * | 1995-06-06 | 2000-08-22 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
AU3454197A (en) | 1996-07-11 | 1998-02-09 | Molins Plc | Web cutting and/or sealing method and apparatus |
US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
ES2247676T3 (es) * | 1997-01-07 | 2006-03-01 | Amylin Pharmaceuticals, Inc. | Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia. |
AU6586298A (en) | 1997-03-31 | 1998-10-22 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
US5955594A (en) * | 1997-04-30 | 1999-09-21 | Mishra; Lopa | Nucleic acids encoding proteins for early liver development |
MY155270A (en) † | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
US20020061838A1 (en) | 2000-05-17 | 2002-05-23 | Barton Holmquist | Peptide pharmaceutical formulations |
-
1999
- 1999-04-30 US US09/302,596 patent/US6284725B1/en not_active Expired - Lifetime
-
2000
- 2000-04-27 PT PT00926404T patent/PT1173197E/pt unknown
- 2000-04-27 DE DE60016393T patent/DE60016393T3/de not_active Expired - Lifetime
- 2000-04-27 MX MXPA01010859A patent/MXPA01010859A/es active IP Right Grant
- 2000-04-27 JP JP2000615022A patent/JP2002543142A/ja active Pending
- 2000-04-27 ES ES00926404T patent/ES2233366T5/es not_active Expired - Lifetime
- 2000-04-27 CA CA2372947A patent/CA2372947C/en not_active Expired - Lifetime
- 2000-04-27 EP EP04027507A patent/EP1512410A1/de not_active Withdrawn
- 2000-04-27 IL IL14583000A patent/IL145830A0/xx unknown
- 2000-04-27 WO PCT/US2000/011251 patent/WO2000066138A2/en active IP Right Grant
- 2000-04-27 AU AU44935/00A patent/AU777019B2/en not_active Ceased
- 2000-04-27 AT AT00926404T patent/ATE283701T1/de active
- 2000-04-27 EP EP00926404A patent/EP1173197B2/de not_active Expired - Lifetime
- 2000-04-27 NZ NZ514610A patent/NZ514610A/xx not_active IP Right Cessation
- 2000-04-27 CN CN00806951A patent/CN1349409A/zh active Pending
-
2001
- 2001-05-09 US US09/851,738 patent/US6982248B2/en not_active Expired - Fee Related
- 2001-09-11 US US09/953,021 patent/US20020147131A1/en not_active Abandoned
- 2001-10-08 IL IL145830A patent/IL145830A/en not_active IP Right Cessation
- 2001-10-29 NO NO20015294A patent/NO325601B1/no not_active IP Right Cessation
-
2002
- 2002-11-13 HK HK02108203.4A patent/HK1046640A1/zh unknown
-
2004
- 2004-12-21 AU AU2004240247A patent/AU2004240247B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
NZ514610A (en) | 2004-01-30 |
WO2000066138A3 (en) | 2001-07-05 |
ES2233366T3 (es) | 2005-06-16 |
AU2004240247B2 (en) | 2008-07-31 |
AU777019B2 (en) | 2004-09-30 |
EP1173197B2 (de) | 2011-10-19 |
NO20015294L (no) | 2001-12-28 |
HK1046640A1 (zh) | 2003-01-24 |
AU2004240247A1 (en) | 2005-01-20 |
NO325601B1 (no) | 2008-06-23 |
US20020147131A1 (en) | 2002-10-10 |
JP2002543142A (ja) | 2002-12-17 |
NO20015294D0 (no) | 2001-10-29 |
WO2000066138A2 (en) | 2000-11-09 |
DE60016393T3 (de) | 2012-07-12 |
CA2372947C (en) | 2013-02-19 |
AU4493500A (en) | 2000-11-17 |
IL145830A0 (en) | 2002-07-25 |
MXPA01010859A (es) | 2002-05-06 |
IL145830A (en) | 2010-12-30 |
PT1173197E (pt) | 2005-04-29 |
ES2233366T5 (es) | 2012-01-27 |
CN1349409A (zh) | 2002-05-15 |
ATE283701T1 (de) | 2004-12-15 |
US6284725B1 (en) | 2001-09-04 |
DE60016393T2 (de) | 2006-02-02 |
EP1173197B1 (de) | 2004-12-01 |
US20020055460A1 (en) | 2002-05-09 |
US6982248B2 (en) | 2006-01-03 |
EP1512410A1 (de) | 2005-03-09 |
EP1173197A2 (de) | 2002-01-23 |
CA2372947A1 (en) | 2000-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE283701T1 (de) | Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe | |
BR0111800A (pt) | Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus | |
UY27069A1 (es) | Activadores de glucocinasa del tipo isoindolin-1-ona | |
BR0014525A (pt) | Processo de tratamento de distúrbios metabólicos, especialmente diabetes, ou uma doença ou condição associada com diabetes | |
ATE203669T1 (de) | Verwendung von r-(+)alpha-liponsäure, r(-)- dihydroliponsäure und metabolite zur behandlung von diabetes mellitus sowie seiner folgeerkrankungen | |
DE69806246T2 (de) | Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika | |
DE60327771D1 (de) | Glp-1 und behandlungsmethode für diabetes | |
CO5011115A1 (es) | Compuestos y metodos quimioquina | |
NZ514609A (en) | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain | |
BR9913833A (pt) | Método para tratar diabetes, empregando em inibidor de ap2 e combinação | |
DK1632483T3 (da) | Heterocykliske, substituerede carbonylderivater og deres anvendelse som dopamin-D3-receptorligander | |
JP2002532432A5 (de) | ||
DE60121145D1 (de) | Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln | |
DE69328186T2 (de) | Zusammensetzung zur behandlung der parkinson-krankheit | |
DE60026146D1 (de) | Verwendung von dapoxetin, a selektiver serotonin-aufnahme inhibitor mit schnellem wirkungseintritt, zur behandlung von sexueller dysfunction | |
DK0988059T3 (da) | Humane quinonreduktase-2-konjugater til ADEPT og GDEPT | |
ATE187642T1 (de) | Verwendund von norastemizol zur behandlung der allergischen rhinitis | |
ATE516366T1 (de) | Regulierte aptamer-therapeutika | |
NZ516290A (en) | Substituted phenoxyacetic acids | |
BR0016831A (pt) | Composição terapêutica e lente de contato impregnada pela mesma | |
DE60320034D1 (de) | Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin | |
DE69111974T2 (de) | Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum. | |
PE108199A1 (es) | Composicion farmaceutica de tiazolidindiona y sulfonilurea | |
ATE382367T1 (de) | Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern | |
MX12192A (es) | Composicion farmaceutica para reducir o impedir las arritmias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
R102 | Epo decision maintaining patent in amended form now final |
Ref document number: 1173197 Country of ref document: EP |